Dalteparin
Administration
- Type: Anticoagulant (Low molecular weight heparin)
- Dosage Forms:
- Routes of Administration: Subcutaneous
- Common Trade Names: Fragmin
Adult Dosing
- PE/DVT treatment: 200 units/kg SC q24h, max 18,000 units
- VTE prophylaxis: 2500-5000 units subQ daily
Pediatric Dosing
Safety/efficacy not established
- PE/DVT treatment: 129 +/- 43 units/kg subQ daily, adjust dose to goal anti-Xa activity 0.5-1 unit/mL 4-6 hours after injection
- VTE prophylaxis: 92 +/- 52 units/kg subQ daily
Special Populations
- Pregnancy Rating: B
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing:
- Hepatic dosing:
Contraindications
- Allergy to class/drug
- Active major bleeding
- History of heparin-induced thrombocytopenia
- Use for VTE prophylaxis or to treat NSTEMI/UA in patients undergoing neuraxial or epidural anesthesia
Adverse Reactions
Serious
- Major bleeding: epidural hematoma, spinal hematoma, intracranial hemorrhage, subdural hemorrhage, hemorrhagic stroke, intrauterine hemorrhage
- Thrombocytopenia
- Paralysis
Common
- Injection site hematoma, pain, irritation
Pharmacology
- Half-life: 3-5h
- Metabolism:
- Excretion: Renal
Mechanism of Action
- Low-molecular weight heparin: binds antithrombin and inhibits coagulation Factor Xa and thrombin
Comments
See Also
- Low molecular weight heparin, unfractionated heparin
- Anticoagulant reversal for life-threatening bleeds